We are delighted to announce the Hardman & Co Tax Advantaged Forum, “Innovation, deep tech and scale-up EIS investing”, in association with GrowthInvest.
Register now to save your spot.
You’ll get the chance to hear from some leading fund managers, presenting exciting investment opportunities. The event will start with an introduction to EIS/SEIS and an update on current themes, followed by the funds presenting their investment case with a live Q&A.
This is a valuable opportunity to broaden your investment options.
We encourage you to register early for the event to secure your place. Sign up on Zoom to hear about “Innovation, deep tech and scale-up EIS investing” from our presenters.
EverQuest Capital Partners is a venture capital firm backing high-growth and scale-up businesses across the supply chain. It focuses on value-driven sectors with strong near-term exit potential. EverQuest backs disruptive enabling technologies that power the UK industry and invests in Deep MakeTech: advanced processes, materials, and design technologies transforming British manufacturing, with a broad exposure across semiconductors, healthcare, renewables, automotive, agriculture and defence. The company manages both the EverQuest EIS Fund and the CPI Evergreen Fund. 50% of its portfolio companies 2x in value in the last 12 months, and EverQuest is trusted by co-investors including BGF, Northern Gritstone and Maven.
EverQuest’s model combines venture investment with deep technical insight through its partnership with CPI (Centre for Process Innovation), providing access to proprietary deal flow and a network of technical expertise that supports portfolio companies in scaling advanced manufacturing technologies globally. Recent deployments include leading TaiSan’s £4.65m seed round in sodium-ion battery technology.
Dr Stephane Mery, Partner: Stephane has over 20 years’ experience in private equity and entrepreneurship. He was CEO of BBSF, an early-stage fund behind the success of Spirogen (sold to Astra Zeneca for $400m), and Endomagnetics (sold for $310m to Hologic). He was also partner at Beringea, leading investments in Life Sciences and Renewables including Biovex (sold for $1bn to Amgen). Stephane turned around and successfully exited a company manufacturing and selling laboratory monitoring equipment. Stephane is a Doctor in Veterinary Medicine, a Veterinary Pathologist and holds an MBA from INSEAD.
Peter Smith, Partner: Peter has significant experience in private equity and corporate finance, previously working with Maven Capital Partners and CPI Enterprises. Peter has led and worked on a number of the most successful transactions during his tenure, including that of Pragmatic (raised over £150m). He has supported a range of fast-growing businesses including Qkine, Q5D, iPac, Descycle. He is responsible for new investments and has overall responsibility for all aspects of the business including strategy, client management and business development. Peter holds an MSc in Finance from Warwick Business School and a first-class degree in Mathematics with Finance from Liverpool University.
MMC Ventures is a venture capital firm built by a multi-generational team with diverse backgrounds. For over two decades, it has partnered with over 100 early-stage founders to help them grow their start-ups. As a research-led investor, it has a deep appreciation for the emerging technologies that are reshaping the future economy.
Its EIS Fund, launched in 2005, offers investors exposure to a portfolio of early stage, private UK technology companies in sub-sectors including fintech, data-driven health, enterprise AI and cloud & data infrastructure. For each investor’s subscription, MMC targets investment in ca.10 EIS qualifying companies within 18-24 months, and the target return is 2-3 times capital invested or above (excluding EIS tax reliefs) over an investment term of at least 5-10 years from the initial investment.
Nishil Patel, Director and Head of Private Client Fundraising: Nishil leads the firm’s fundraising strategy across its private client investor base and oversees MMC’s Syndicate offering. He works closely with investors, advisers and founders, as a trusted adviser across the MMC ecosystem, helping to expand MMC’s investor network and fundraising capabilities. Nishil joined MMC in 2017 to support the growth of the firm’s business development function.
Parkwalk is the UK’s most active investor in university spinouts, backing transformative technologies developed by the country’s leading universities and research organisations. Parkwalk focuses on investing in companies addressing real-world challenges with IP-protected innovations across a broad range of sectors, including life sciences, artificial intelligence, quantum computing, advanced materials, genomics, cleantech, future mobility, medtech and big data.
As the leading growth EIS fund manager, with £400 million in assets under management, Parkwalk has invested in over 200 companies through its Parkwalk Opportunities and Knowledge Intensive EIS Funds, as well as through enterprise and innovation funds managed for the Universities of Cambridge, Oxford, Bristol and Imperial College. In 2025, Parkwalk introduced the Northern Universities Venture Fund, targeting opportunities emerging from the Universities of Leeds, Liverpool, Manchester and Sheffield.
Susie Harris, Director, Business Development: Susie is responsible for the overall fundraising strategy at Parkwalk, as well as managing strategic partnerships. She spends much of her time presenting Parkwalk’s funds to investors, private clients and wealth managers but also works on the marketing for Parkwalk’s EIS Funds. Prior to joining Parkwalk, Susie was Head of Internal Business Development at Puma Investments. She has spent most of her career marketing tax-advantaged products and sits on the EIS & VCT Subcommittee for UK Private Capital and the Research & Education Committee for the EIS Association (EISA).
